Grace Therapeutics Inc. Common Stock (GRCE)

FairStock Score: 64/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Grace Therapeutics as a Graham-style analyst: what am I buying, and what is the margin of safety? The company is a five-employee biotech developing rare-disease products, including GTX-104 for aneurysmal subarachnoid hemorrhage, GTX-102 for Ataxia-Telangiectasia, and GTX-101 for pain. But the filed figures show no revenue in any period listed. In fiscal Q1 2027, the quarter ended 2026-06-30, the net loss was $15.8 million, or $0.91 per diluted share. That is a sharp deterioration from fiscal Q2 2026, the quarter ended 2025-09-30, when the net loss was $938,000, or $0.06 per share, and fiscal Q3 2026, the quarter ended 2025-12-31, when it was $2.3 million, or $0.14 per share. Full-year losses narrowed from $12.9 million in FY2024, the year ended 2024-03-31, to $9.6 million in FY2025, the year ended 2025-03-31, and $7.8 million in FY2026, the year ended 2026-03-31, but the latest quarter breaks that trend. There is no earnings stream, no reported revenue, and trailing free cash flow was negative $10.3 million, a negative 24.6% FCF yield on the $41.9 million market cap at the 2026-10-13 close. FairStock ratios show a negative P/E of -1.70, P/B of 0.67, ROE of -36.19%, and a Piotroski F-Score of 1/9. The low P/B and Altman Z-Score of 6.97 are not enough for me without a durable business or earnings. The Lynch category is 'none' because it has lost money in each of the last four years. A pipeline can create value if approved, but until revenue and positive cash flow appear, this is a speculative development story, not a proven compounding business.

In plain English: The company is a tiny drug developer focused on rare diseases. It has no reported sales and keeps losing money, so the business looks weak. The stock trades below its stated accounting net assets, but with no revenue or profits it is hard to call cheap; it looks speculative rather than clearly inexpensive.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q1 2027 10-Q (period ended 2026-06-30) · fiscal Q3 2026 10-Q (period ended 2025-12-31) · fiscal Q2 2026 10-Q (period ended 2025-09-30) · fiscal Q1 2026 10-Q (period ended 2025-06-30) · FY2026 10-K (period ended 2026-03-31) · FY2025 10-K (period ended 2025-03-31) · FY2024 10-K (period ended 2024-03-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer